The DOI matches its Crossref record; the references it cites are not checked yet; 95 of the 162 sources its claims cite were checked for support.
Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review
Open accessAbstract
Background: With rising obesity rates, pharmacological interventions are increasingly used in non-diabetic adults. While being effective in managing weight, these agents frequently cause gastrointestinal (GI) side effects, affecting adherence and long-term outcomes. Objective: To systematically evaluate the frequency, severity, and types of GI adverse effects (AEs) associated with anti-obesity medications in obese adults without diabetes. Methods: Following PRISMA 2020 guidelines, PubMed, Google Scholar, BMJ, and Web of Science were searched (last search July 2025). Eligible studies included randomized controlled trials, non-randomized trials, cohort studies, cross-sectional, and case–control studies. Only reports of GI AEs in non-diabetic adults were included. Risk of bias was assessed using Cochrane RoB 2 and Newcastle–Ottawa scales. Results: Out of 733 articles screened, 12 studies met predefined inclusion criteria, including one large cohort of 18,386 participants, along with randomized and observational trials of smaller size. The most frequently reported GI symptoms were nausea, vomiting, diarrhea, and constipation, predominantly with GLP-1 receptor agonists such as semaglutide and tirzepatide, especially during dose escalation. Orlistat commonly linked to steatorrhea and flatulence, while phentermine was associated with reduced GI motility. Newer agents, including retatrutide and orforglipron, also demonstrated notable GI side effect profiles. Natural products and investigational agents reported fewer adverse events but lacked long-term data and standardized reporting. Limitations: Evidence was limited by heterogeneity in study design and inconsistent reporting of GI outcomes. Conclusion: GI side effects are common across anti-obesity medications, particularly GLP-1 receptor agonists. Although generally mild to moderate, these symptoms can impact adherence and lead to treatment discontinuation. Tailored titration schedules, proactive patient counseling, and standardized adverse event reporting may improve tolerability. Further research is warranted to evaluate long-term GI outcomes and compare safety across emerging pharmacologic agents.
Overview
CoChat Summary
TL;DR
This systematic review of 12 studies found gastrointestinal adverse effects are common with anti-obesity medications in non-diabetic adults, especially GLP-1 receptor agonists, and are generally mild to moderate and peak during dose escalation. Discontinuation due to GI events ranged roughly 1–17%, highest with high-dose incretin-based therapies.
Key findings
- Across 12 included studies, GI AEs were the most frequent treatment-emergent events; nausea, vomiting, diarrhea, and constipation predominated, especially with GLP-1 receptor agonists such as semaglutide and tirzepatide during dose escalation. In STEP 1, GI disorders occurred in 74.2% with semaglutide vs. 47.9% with placebo; nausea 44.2% vs. 17.4%, diarrhea 31.5% vs. 15.9%, vomiting 24.8% vs. 6.6%, constipation 23.4% vs. 9.5%, and discontinuation due to GI events 4.5% vs. 0.8%.
- Orlistat was consistently associated with oily stools, fecal urgency, and flatulence with discharge in 15–30% of users. Phentermine 15 mg produced abdominal pain 0.5%, constipation 3.5%, dry mouth 6.3%, nausea 0.5%, and vomiting 0.3%; at 30 mg, rates were 2.4%, 4.1%, 13.9%, 1.1%, and 0.8%, respectively.
- In a comparative cohort of 18,386 participants, semaglutide vs. tirzepatide showed similar event rates per 1000 person-years: bowel obstruction 6.26 vs. 5.54 (HR 1.12; 95% CI 0.63–1.97), cholecystitis 6.5 vs. 5.06 (HR 1.25; 95% CI 0.70–2.21), cholelithiasis 11.89 vs. 12.66 (HR 0.94; 95% CI 0.63–1.39), and gastroenteritis 19.75 vs. 20.07 (HR 1.00; 95% CI 0.73–1.37).
- Discontinuation due to GI events ranged roughly 1–17%, highest with high-dose incretin-based therapies; gallbladder-related events were uncommon (<2%) but slightly more prevalent with incretin drugs. Natural and investigational agents produced the fewest reported GI events but were supported by small, short-term studies.
Methods
- PRISMA 2020 systematic review prospectively registered in PROSPERO (CRD420251113277); searched PubMed, Google Scholar, BMJ archive, and Web of Science, with last search July 2025. Eligible studies included randomized controlled trials, non-randomized trials, cohort studies, cross-sectional studies, case–control studies, and interventional clinical trials in English, published 2020–2025, in non-diabetic adults ≥18 years.
- From 733 records identified, 12 studies met all inclusion criteria and were included; one large cohort had 18,386 participants. Risk of bias was assessed with Cochrane RoB 2 and Newcastle–Ottawa scales, with articles scoring above 70% considered eligible.
- A quantitative meta-analysis was not feasible due to heterogeneity in study design, outcome definitions, and reporting methods; findings were synthesized narratively. No formal GRADE scoring, publication bias testing, subgroup analysis, or sensitivity analysis was conducted.
Limitations
- The paper states that evidence was limited by heterogeneity in study design and inconsistent reporting of GI outcomes; meta-analysis was not feasible, formal GRADE and publication bias testing were not performed, and few studies addressed potential confounders such as preexisting GI conditions, dietary patterns, or concomitant medication use.
- The paper states that symptom grading was inconsistent, no study used GI-specific severity frameworks such as CTCAE, and none assessed patient satisfaction or GI symptom-specific quality-of-life instruments; natural and investigational products relied on limited short-term data.
- Evident from the text: only English-language articles from 2020–2025 were included, no separate detailed protocol was prepared, no amendments were made to the registration, and reporting bias was not formally assessed because unpublished data and trial registries were outside the review’s scope.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
42 Valid · 4 Not valid · 29 Not checked · 54 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Incretin-based therapies (semaglutide, liraglutide, exenatide) showed clear dose-dependent increase in nausea and diarrhea across both trials and real-world datasets [6,8,9,10,11].”
§ Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review > 1. Introduction
What the sources say
- Partly supportedcites [6] Rubino, 2021, Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial, JAMA sourceExperimental — accuracy not yet measured
STEP 4 (Table 3, Conclusions section, and Adverse Events and Tolerability) does document more nausea (14.0% vs 4.9%) and diarrhea (14.4% vs 7.1%) with subcutaneous semaglutide 2.4 mg than placebo in adults with overweight/obesity, plus the Discussion's observation that gastrointestinal events were more frequent during the 20-week dose-escalation run-in than during the randomized period. But the trial randomized only one maintenance dose (2.4 mg) against placebo, so it provides no dose-ranging/dose-dependent comparison, and it says nothing about liraglutide or exenatide (those appear only in its reference list, e.g. refs 14, 15, 29, 30) nor about real-world datasets. The class-wide, multi-agent, dose-dependent and real-world portions of the claim are therefore not attributable to this source; only the semaglutide-specific excess of nausea and diarrhea is. (LLM, conf=0.75)
- Disputedcites [8] Rodriguez, 2024, Semaglutide vs Tirzepatide for Weight Loss in Adults with Overweight or Obesity, JAMA Intern. Med. sourceExperimental — accuracy not yet measured
The cited study is a real-world EHR cohort of semaglutide vs tirzepatide (T2D-labeled formulations) and does not report any dose-dependent rise in nausea or diarrhea: its Safety Outcomes section states that mild AEs such as nausea and vomiting 'were not included given the expectation of inconsistent capture in EHR data,' and its Gastrointestinal Adverse Events section reports 'no significant differences in the risk of any gastrointestinal AEs' between the two drugs (Abstract: 'Rates of gastrointestinal AEs were similar between groups'). It also performed no dose-response analysis — the Strengths and Limitations section notes 'we relied on brand as a proxy for target dose' — and it is not a trial; liraglutide appears only as a weight-outcome validation analysis in supplements, and exenatide is not studied. So the part attributed here (dose-dependent nausea/diarrhea in real-world data) is contrary to what the paper says about nausea capture and GI AE findings. (LLM, conf=0.68)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [9] Rodgers, M., Migdal, A.L., Rodríguez, T.G., Chen, Z.-Z., Nath, A.K., Gerszten, R.E., Kasid, N., Toschi, E., Tripaldi, J., and Heineman, B. (2021). Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women. Front. Endocrinol., 12. sourceExperimental — accuracy not yet measured
The Results > Adverse Events section (p. n/a) supports only part of the attributed claim: in this randomized, placebo-controlled trial, nausea was significantly more common with exenatide than diet/placebo (70% vs 25%, p<0.0001), and the Discussion repeats that nausea and decreased appetite were more prevalent in the exenatide group. Diarrhea is not reported anywhere in our copy (searched: diarrhea/vomiting/constipation/gastrointestinal), and no dose-dependence is shown — exenatide was titrated to a single maximum dose of 10 mcg twice daily with no comparator dose arms, and the paper notes nausea decreased over time rather than rising with dose. The semaglutide and liraglutide data the paper cites (O'Neil 2018, STEP 3) are reported only as weight-loss responder percentages, not adverse-event rates, and no real-world/post-marketing dataset is analyzed. (LLM, conf=0.72)
- Partly supportedcites [10] Lundgren, 2021, Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
Our copy of Lundgren et al. (2021) supports only part of the claim: the Safety section and Table 2 (reported in the Discussion pages) show that gastrointestinal adverse events — nausea (65% liraglutide, 53% combination vs 16% placebo) and diarrhea (27% and 29% vs 8% placebo) — were more frequent in the liraglutide-containing arms of this single randomized trial. The dose-dependent element is not supported: all liraglutide-treated participants were titrated to the same 3.0 mg/day target (Interventions; mean achieved dose 2.8 mg/day, Adherence to Interventions), and no dose-response analysis of nausea or diarrhea is reported. Nor does the paper cover semaglutide or exenatide as interventions (semaglutide appears only as an external weight-loss comparison in the Discussion) or any real-world dataset — it is a placebo-controlled trial in 195 overweight/obese adults after low-calorie-diet-induced weight loss. (LLM, conf=0.75)
- Not checked yetcites [11] Zhao, 2024, Tirzepatide for Weight Reduction in Chinese Adults with Obesity: The SURMOUNT-CN Randomized Clinical Trial, JAMA source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“This temporal pattern supports the role of delayed gastric emptying and vagal stimulation as mechanistic pathways underlying nausea and early satiety in incretin-based therapies [8,11,12].”
§ Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review > 4. Discussion > 4.2. Cross-Class Patterns and Mechanistic Insights
What the sources say
- Disputedcites [8] Rodriguez, 2024, Semaglutide vs Tirzepatide for Weight Loss in Adults with Overweight or Obesity, JAMA Intern. Med. sourceExperimental — accuracy not yet measured
Our copy of Rodriguez et al. (JAMA Intern Med 2024) explicitly excluded the events the claim rests on: the Safety Outcomes section states that only moderate-to-severe GI AEs (bowel obstruction, cholecystitis, cholelithiasis, gastroenteritis, gastroparesis, pancreatitis) were identified, and that 'Mild AEs, such as nausea and vomiting, were not included given the expectation of inconsistent capture in EHR data.' The Gastrointestinal Adverse Events results report only 'no significant differences in the risk of any gastrointestinal AEs between those receiving tirzepatide vs semaglutide,' with no temporal-pattern analysis, and no passage anywhere in our copy discusses delayed gastric emptying, vagal stimulation, or early satiety as mechanisms. So the paper's contrary statement that it did not capture nausea, plus its null comparative AE findings, cannot support the mechanistic inference attributed to it. (LLM, conf=0.62)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [11] Zhao, 2024, Tirzepatide for Weight Reduction in Chinese Adults with Obesity: The SURMOUNT-CN Randomized Clinical Trial, JAMA source
- Partly supportedcites [12] Aronne, 2024, Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial, JAMA sourceExperimental — accuracy not yet measured
SURMOUNT-4 (Results, 'Adverse Events and Tolerability') does report the temporal pattern the citing sentence rests on: gastrointestinal events were mostly mild to moderate and the incidence of new events decreased over time during the tirzepatide lead-in period and levelled off during the double-blind period (with nausea 35.5% in lead-in vs 8.1% vs 2.7% in the double-blind period). However, our copy makes no mechanistic claim at all — searches for 'delayed gastric emptying', 'vagal stimulation' and 'early satiety' return nothing; the paper only notes that dose-escalation protocols 'helped to maximize tolerability' (Discussion, Limitations/strengths) and that the safety profile is consistent with prior incretin trials (Discussion). The inference to gastric emptying and vagal stimulation as the pathways underlying nausea and early satiety is therefore not attributable to this source. (LLM, conf=0.75)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Gallbladder-related events and rare pancreatitis cases were more frequently observed with GLP-1 based drugs, consistent with their known effects on biliary motility and lipid metabolism rather than direct pancreatic toxicity [4,6,13].”
§ Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review > 4. Discussion > 4.2. Cross-Class Patterns and Mechanistic Insights
What the sources say
- Not checked yetcites [4] Jastreboff, 2023, Triple-Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial, N. Engl. J. Med. source
- Disputedcites [6] Rubino, 2021, Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial, JAMA sourceExperimental — accuracy not yet measured
STEP 4 reports the opposite direction for the biliary endpoint: in the Adverse Events and Tolerability section, gallbladder-related disorders (mostly cholelithiasis) occurred in 2.8% of participants receiving continued semaglutide vs 3.7% switched to placebo during the randomized period (Table 3: 15 [2.8%] vs 10 [3.7%]; 3.1 vs 4.1 events per 100 patient-years). Pancreatitis was not increased with the GLP-1 drug either: Table 3 lists 0 acute pancreatitis events in both arms during randomization, with a single moderate case arising during the semaglutide run-in (Outcomes section notes pancreatitis events were sent to an independent adjudication committee). Our copy nowhere offers the mechanistic attribution in the claim (effects on biliary motility or lipid metabolism vs direct pancreatic toxicity), so that explanatory part is unsupported as well. (LLM, conf=0.80)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [13] Wilding, 2021, Once-Weekly Semaglutide in Adults with Overweight or Obesity, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
Our copy supports the observational half: the Safety and Side-Effect Profile (p. 1001) reports gallbladder-related disorders (mostly cholelithiasis) in 2.6% vs 1.2% (semaglutide vs placebo) and three mild, adjudicated acute-pancreatitis cases, all in the semaglutide group, and the Discussion (p. 1002) states these gallbladder findings were 'consistent with previous reports for GLP-1 receptor agonists and with the known effects of rapid weight loss.' The mechanistic attribution the citing sentence carries — biliary motility and lipid metabolism rather than direct pancreatic toxicity — is not in this paper: searches for biliary motility/gallbladder emptying, cholesterol or lipid-bile mechanisms and any pancreatic-toxicity argument returned no such statement; the source invokes rapid weight loss and prior GLP-1 RA reports instead, and only notes 'no new safety concerns arose.' So the mechanism clause is not supported by this source. (LLM, conf=0.80)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Multiple trials reported the most commonly observed AEs included nausea, diarrhea, constipation, and abdominal discomfort [3,6,9,12,13].”
§ Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review > 1. Introduction
What the sources say
- Not checked yetcites [3] 2025, Three- and six-month efficacy and safety of phentermine in a Mexican obese population, Int. J. Clin. Pharmacol. Ther.
- Supportedcites [6] Rubino, 2021, Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults with Overweight or Obesity: The STEP 4 Randomized Clinical Trial, JAMA source
Table 3 (Adverse Event and Tolerability Profile, weeks 20-68) lists the adverse events reported in ≥5% of participants in the continued-semaglutide arm, and the three most frequent are diarrhea (14.4%), nausea (14.0%) and constipation (11.6%), with abdominal pain also in that list (6.5%); the citing sentence's 'abdominal discomfort' corresponds to the trial's 'abdominal pain' term. The Adverse Events and Tolerability text further supports the predominance of GI events (41.9% vs 26.1% with placebo, mostly mild to moderate). Since the claim is non-exhaustive ('included'), the omission of nasopharyngitis/vomiting does not weaken it. (LLM, conf=0.85)
- Partly supportedcites [9] Rodgers, M., Migdal, A.L., Rodríguez, T.G., Chen, Z.-Z., Nath, A.K., Gerszten, R.E., Kasid, N., Toschi, E., Tripaldi, J., and Heineman, B. (2021). Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women. Front. Endocrinol., 12. sourceExperimental — accuracy not yet measured
The Results 'Adverse Events' section (and the Discussion) of Rodgers et al. 2021 state that the most common adverse events were nausea (57%), decreased appetite (36%) and headache (26%), with nausea significantly higher on exenatide (70% vs 25%) — so nausea is supported. Diarrhea, constipation and abdominal discomfort are not reported anywhere in our copy (searched: diarrhea/constipation/abdominal discomfort, gastrointestinal adverse events, tolerability/safety), and this paper is a single randomized trial in overweight/obese women, not 'multiple trials'. The three non-nausea GI events attributed to this source are unsupported. (LLM, conf=0.78)
- Partly supportedcites [12] Aronne, 2024, Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity: The SURMOUNT-4 Randomized Clinical Trial, JAMA sourceExperimental — accuracy not yet measured
In the Results (Adverse Events and Tolerability), SURMOUNT-4 does report the most frequent treatment-emergent adverse events during the tirzepatide lead-in period as gastrointestinal — nausea (35.5%), diarrhea (21.1%) and constipation (20.7%) — supporting three of the four events the citing sentence attributes. However, the fourth listed event is vomiting (16.3%), not abdominal discomfort; abdominal pain appears in Table 3 only as a rare serious event (0.3% in the tirzepatide group) and in the footnote on serious gastrointestinal events, so 'abdominal discomfort' as a most commonly observed AE is not supported by this source. The paper also frames these frequencies for the open-label lead-in phase, whereas its double-blind period most frequent events were COVID-19 and diarrhea/nausea/vomiting. (LLM, conf=0.78)
- Supportedcites [13] Wilding, 2021, Once-Weekly Semaglutide in Adults with Overweight or Obesity, N. Engl. J. Med. source
The Safety and Side-Effect Profile section states that 'Gastrointestinal disorders (typically nausea, diarrhea, vomiting, and constipation) were the most frequently reported events', and Table 3 lists the adverse events reported in ≥10% of participants as nausea (44.2%), diarrhea (31.5%), vomiting (24.8%), constipation (23.4%), dyspepsia (10.3%) and abdominal pain (10.0%) in the semaglutide arm — so nausea, diarrhea, constipation and abdominal discomfort (abdominal pain/dyspepsia) are all among the most commonly observed AEs in this trial. The Discussion likewise describes transient, mild-to-moderate gastrointestinal disorders as the most frequently reported adverse events, with nausea the most common. The claim's 'multiple trials' framing spans the other citations in the series; for this source the substance is supported. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Nausea occurred in 44.2% vs. 17.4%, diarrhea 31.5% vs. 15.9%, vomiting 24.8% vs. 6.6%, and constipation 23.4% vs. 9.5%.”
§ Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review > 3. Results > 3.3. Summary of Gastrointestinal Adverse Effects Across Studies
What the sources say
- Supportedcites [13] Wilding, 2021, Once-Weekly Semaglutide in Adults with Overweight or Obesity, N. Engl. J. Med. source
Table 3 (p. 1000) reports constipation in 306 of 1306 semaglutide participants (23.4%) and 62 of 655 placebo participants (9.5%) in the STEP 1 safety population. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
67 more claims · 34 with their cited sources checked
Create a free account to see all 129 claims and to verify the 67 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 49
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Early mechanistic and clinical studies suggest additive or synergistic effects on glycemic control and weight loss when GLP-1 receptor agonists are combined with SGLT2 inhibition, without a proportional increase in hypoglycemia risk [85,99,100].”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review > 3. Results
“After screening 733 titles and abstracts, 605 were excluded.”
§ Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review > 3. Results
“A total of 733 records were identified, of which three duplicates and one record not in English were removed.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review > 2. Methodology > 2.2. Eligibility Criteria
“These criteria ensured that only peer-reviewed interventional studies in non-diabetic adults (≥18 years) evaluating gastrointestinal adverse effects of anti-obesity medications between 2020 and 2025 were retained.”
§ Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review > Abstract
“Out of 733 articles screened, 12 studies met predefined inclusion criteria, including one large cohort of 18,386 participants, along with randomized and observational trials of smaller size.”
Citations
The citation lists are queued
They are fetched later and appear here then.
References 24 · Cited by 13
Metadata
- Authors
- Takrori, E., Peshin, S., & Singal, S.
- Affiliations
- Alfaisal University (SA)
- Norton Community Hospital (US)
- East Tennessee State University (US)
- Corresponding author
- Peshin, Supriya
- Venue
- Medicina
- Publisher
- MDPI AG
- Published
- 2025-11-05
- Volume
- 61
- Issue
- 11
- Pages
- 1987
- ISSN
- 1010-660X (ISSN-L)
- 1648-9144
- PMC
- PMC12654588
- OpenAlex
- W4415929925
- Cited by
- 13
- References
- 24
- Citations by year
- 2026: 12 · 2025: 1
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Medicina (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- anti-obesity drugs, gastrointestinal adverse effects, non-diabetic adults, obesity, GLP-1 receptor agonists, semaglutide, tirzepatide, orlistat, phentermine, retatrutide, orforglipron, nausea, vomiting, diarrhea, constipation, steatorrhea, medication adherence, dose escalation
- MeSH terms
- Adult, Gastrointestinal Diseases, Humans, Obesity, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review. https://app.cochat.ai/papers/10.3390/medicina61111987
- The paper
- Takrori, E., Peshin, S., & Singal, S. (2025). Gastrointestinal Adverse Effects of Anti-Obesity Medications in Non-Diabetic Adults: A Systematic Review. Medicina. https://doi.org/10.3390/medicina61111987
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
